Hoylecohen LLC Purchases 327 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Hoylecohen LLC raised its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 1.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 22,830 shares of the biopharmaceutical company’s stock after acquiring an additional 327 shares during the period. Hoylecohen LLC’s holdings in Gilead Sciences were worth $1,849,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Etesian Wealth Advisors Inc. raised its position in Gilead Sciences by 0.7% during the fourth quarter. Etesian Wealth Advisors Inc. now owns 18,318 shares of the biopharmaceutical company’s stock valued at $1,486,000 after purchasing an additional 128 shares during the period. Financial Counselors Inc. lifted its position in Gilead Sciences by 1.5% in the fourth quarter. Financial Counselors Inc. now owns 8,862 shares of the biopharmaceutical company’s stock worth $718,000 after buying an additional 128 shares during the last quarter. Revolve Wealth Partners LLC boosted its stake in Gilead Sciences by 3.7% during the fourth quarter. Revolve Wealth Partners LLC now owns 3,607 shares of the biopharmaceutical company’s stock worth $292,000 after buying an additional 130 shares during the period. Institutional & Family Asset Management LLC increased its position in Gilead Sciences by 10.3% during the third quarter. Institutional & Family Asset Management LLC now owns 1,501 shares of the biopharmaceutical company’s stock valued at $112,000 after acquiring an additional 140 shares during the last quarter. Finally, Choreo LLC raised its stake in shares of Gilead Sciences by 2.8% in the third quarter. Choreo LLC now owns 5,303 shares of the biopharmaceutical company’s stock valued at $397,000 after acquiring an additional 142 shares during the period. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences Stock Down 0.7 %

Shares of GILD stock traded down $0.49 during trading hours on Friday, reaching $65.68. 5,971,044 shares of the company’s stock were exchanged, compared to its average volume of 6,600,837. Gilead Sciences, Inc. has a fifty-two week low of $64.33 and a fifty-two week high of $87.86. The stock’s 50 day moving average is $68.45 and its 200-day moving average is $74.54. The company has a current ratio of 1.08, a quick ratio of 0.94 and a debt-to-equity ratio of 1.31. The company has a market cap of $81.83 billion, a price-to-earnings ratio of 182.44, a P/E/G ratio of 1.32 and a beta of 0.22.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.49) by $0.17. Gilead Sciences had a return on equity of 24.34% and a net margin of 1.76%. The company had revenue of $6.69 billion for the quarter, compared to analyst estimates of $6.36 billion. During the same period in the prior year, the company posted $1.37 EPS. The firm’s quarterly revenue was up 5.3% compared to the same quarter last year. Analysts predict that Gilead Sciences, Inc. will post 3.74 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, June 27th. Investors of record on Friday, June 14th will be paid a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a yield of 4.69%. The ex-dividend date is Friday, June 14th. Gilead Sciences’s dividend payout ratio (DPR) is presently 855.56%.

Insider Buying and Selling

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $72.96, for a total value of $145,920.00. Following the completion of the transaction, the insider now owns 96,304 shares of the company’s stock, valued at $7,026,339.84. The transaction was disclosed in a filing with the SEC, which is available at this link. 0.16% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. Mizuho cut their price target on shares of Gilead Sciences from $101.00 to $90.00 and set a “buy” rating on the stock in a report on Thursday, February 22nd. TD Cowen reduced their price target on Gilead Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a report on Friday, April 26th. HSBC raised shares of Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 target price on the stock in a research report on Wednesday, April 24th. Truist Financial lowered Gilead Sciences from a “buy” rating to a “hold” rating and lowered their price target for the company from $91.00 to $82.00 in a report on Thursday, February 22nd. Finally, Wells Fargo & Company reduced their price objective on Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating on the stock in a report on Monday, March 4th. Eleven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Gilead Sciences presently has an average rating of “Hold” and a consensus target price of $83.69.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.